Nyxoah to Participate in the Oppenheimer 32nd Annual Healthcare Conference
Nyxoah SA announced its participation in the Oppenheimer 32nd Annual Healthcare Conference, scheduled for March 15-17, 2022. The company will present virtually with CEO Olivier Taelman providing a corporate update on March 16 at 10:40 am EST. Nyxoah specializes in innovative solutions for Obstructive Sleep Apnea (OSA) treatment, notably through its lead product, the Genio® system. This system received its CE Mark in 2019 and is currently being studied for FDA approval. Investors can access the live webcast and updated presentations via the company's investor relations page.
- None.
- None.
Nyxoah to Participate in the Oppenheimer 32nd Annual Healthcare Conference
Mont-Saint-Guibert, Belgium – March 10, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the Oppenheimer 32ndAnnual Healthcare Conference, which will be held virtually from March 15-17, 2022.
Olivier Taelman, Nyxoah’s Chief Executive Officer, is scheduled to present a corporate update on Wednesday, March 16, 2022, at 10:40am EST. Please click here to access the live webcast of the presentation. The webcast will also be available on the Eventspage of Nyxoah’s investor relations website.
Nyxoah’s updated Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80
Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494
Attachment
FAQ
What is Nyxoah's participation in the Oppenheimer 32nd Annual Healthcare Conference?
When will Nyxoah's CEO present at the conference?
What is the focus of Nyxoah's medical technology?
What is the Genio® system developed by Nyxoah?
When did Nyxoah receive the CE mark for the Genio® system?
Is the Genio® system approved for use in the United States?
